Drugs / STA363
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03055845 | Mar 2017 → Aug 2019 | — | Stayble Therapeutics | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04673461 | Jul 2020 → Sep 2023 | lumbar disk disease | Stayble Therapeutics | Completed | Missed primary |
Press releases naming this drug 11 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | STA363 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04673461 ↗ |
| Known as | lactic acid | “STA363 (lactic acid) into one or two IVDs compared to placebo for the treatment of discogenic low back pain” NCT04673461 ↗ |
| Route | Other | “Administered as intradiscal injection.” NCT03055845 ↗ |